								
FORM PTO 1449 (S. DEPARTMENT OF CO	MMÉRGE	JC138	ATTY DOCKET NO. 01997.026000.2	APPLICA 09/852			
LIST OF	ATENT AND TRADEMARK REFERENCES CITED BY (Use several sheets if necessity)	APPLICANTIS & T		APPLICANT WILLIAM L. TREPICCHIO ET AL.				
	(and determined in the	TATA TRA	3-4	filing date May 9, 2001		GROUP 1634		
		CAT 6. TRA	OF.	U.S. PATENT DOCUMENTS				
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE		NAME CL		SUBCLASS	FILING DATE IF APPROPRIATE	
			FOE	REIGN PATENT DOCUMENTS				
		T	101	ALIGIT PATENT DOCUMENTS	T			
	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT	
	-							
		OTHER DOCUM	JENT/S)	Including Author, Title, Date, Pertinent Pages, Etc.)	Í			
PN	GenBank dat complete cds	abase acces		no. U09770 "Human cysteine-rich ho	eart prof	ein (hCRH	P) mRNA,	
	GenBank dat mRNA, comp	GenBank database accession no. U58630 "Human cysteine-rich intestinal protein (CRIP) mRNA, complete cds."						
	PARK et al. (Jan. 1999) "Vitamin D receptor polymorphism is associated with psoriasis", J. Invest. Dermatol., vol. 112, no. 1, pp. 113-16.							
	PINCELLI (Ma Dermatol., vo	PINCELLI (Mar. 2000) "Nerve growth factor and keratinocytes: a role in psoriasis", Eur. J. Dermatol., vol. 10, no. 2, pp. 85-90.						
V	KHOO et al. (1996) "Differential expression of cysteine-rich intestinal protein in liver and intestine in CCl₄-induced Inflammation", Am. J. Physiol., vol. 270, pp. G613-18.							
EXAMINER P	NOC	· · · · · · · · · · · · · · · · · · ·		DATE CONSIDERED 6/28/07/				
				DATE CONSIDERED 6/28/04			ll	

Sheet	1	of	1

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	· ເ š					:			t <u>1 o</u> f 2	
REV 7		CSIMILI	E OF FORM PTO-1448	U.S. DEPART COMMERCE PATENT AND	MENT OF TRADEMARK OFFICE	GFN-5405CP		09/852,400	HOH	
LIST OF PUBLICATIONS CITED BY APPLICANT (USB Several sheets if necessary)								CEN	JAN	
		6	1 F Z	·		FILING DATE May 9, 2001		1623	ER	0 7
L	1	1AL	0 2 2002	U.S. PA	ATENT DOC		l.		600	2002
EXAM!	NER AL	ŽŽ.	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	G BLING	DATE
		7	DOCUMBAT NUMBER						(EAPPRO	PRIATE
				FOREIGN	PATENT DO	CUMENTS		***********		·
			DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANS	
									YES	NO.
			OTHERS (inc	ludina Aut	hor Title Da	te, Pertinent Pages,	Etc.)			
Pn	A1		Balendran N, et a	l. Charact	erization of	the major suscepti	bility reg	ion for pso	riasis a	ıt
<u> </u>	A2	1	chromosome 6p21.3. J Invest Dermatol. 1999 Sep;113(3):322-8 Brown RM, et al. Transfection screening for primary defects in the pyruvate dehydrogenase E1alpha subunit gene. Hum Mol Genet. 1997 Aug;6(8):1361-7							
	A3		Capon F, et al. Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. Am J Hum Genet. 1999 Dec;65(6):1798-800							
	A4		Coven TR, et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997 Dec;133(12):1514-22							
	A5		Czubayko F, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997 Oct;3(10):1137-40							
	A6	1	Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8							
	A7		Fredriksson T, et al. Severe psoriasisoral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44							
	A8		Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7							
	A9		Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7							
PN	A10	n 1:22 e	Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9							
Exami	ner	P.	Nolan	<u>```</u>		Date Considered	hu	 		
*EXAN	MINER	₹:	Initial if reference citation if not in c	considered,	whether or not on and not consider	citation is in conformance red. Include copy of this	with MPEP form with ne	609; Draw line	through ion to ap	plicant.

, 🚣 ?			Sheet 2 c	7 of 2—1
APPLICANT FAC	MILE OF FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO	SERIAL NO.	<u> </u>
	E PUBLICATIONS CITED BY APPLICANT	GFN-5405CP	69/852,400	<u> </u>
P	(Use several sheets if necessary)	William L. Trepicchio et		
No.		FILING DATE	GROUP	出 5
JAH O 2	Sous E	May 9, 2001	1623	}
7WIL	OTHERS (including Author, Title, Da	te, Pertinent Pages, Etc.)		7002 600/2900
B1 B1	Krueger JG, et al. Role of growth factor			8
PN	pathogenesis of psoriasis. J Invest Der		<u></u>	
B2	Tamayo P, et al. Interpreting patterns of			
PN	methods and application to hematopoid 1999 Mar 16;96(6):2907-12	etic differentiation. Proc Na	atl Acad Sci U :	S A.
PM B3	Trepicchio WL, et al. Interleukin-11 th	erapy selectively downreg	ulates type I cyt	tokine
/ B4	proinflammatory pathways in psoriasis			1527-37
PN	Trepicchio WL, et al. IL-11 regulates n inhibition of nuclear factor-kappaB. J I	nacrophage effector function mmunol. 1997 Dec 1;159(on through the 11):5661-70	
			, ·	
Evernises				
Examiner	ofrice J-Noc	late Considered		
*EXAMINER:	Initial if reference considered, whether or not c citation if not in conformance and not consider	citation is in conformance with MPEF	609; Draw line thro	ugh o applicant